Halaven
(Eribulin Mesylate)ApprovedSmall molecule
EisaiEribulin mesylate is used to treat certain types of advanced breast cancer and a rare type of cancer called liposarcoma. It works by stopping cancer cells from dividing and growing.[2] Halaven is currently approved and in use across 23 indications[4].[1]
Halaven is one of 575 small molecule programs targeting Salivary Gland Cancer. It is currently in Approved.
23
Indications
70
Total Trials
12
Active Trials
574
Competitors
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 23 indications
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Halaven
EisaiApproved
Blenoxane
Bristol-Myers SquibbPreclinical
Effexor
WWyeth-Lederle Vaccines
Preclinical
Recentin
NNational Cancer Institute (NCI)
Preclinical
Spravato
WWim Janssens
Preclinical
Avastin
RochePreclinical
Nubain
AAultman Health Foundation
Preclinical
Vfend
PPrism Pharmaceuticals
Preclinical
Zoladex
Luye Pharma Group Ltd.Preclinical
Neoadjuvant Therapy
SSun Yat-sen University
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Breast Cancer38 trials
Show 35 more trials
A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast Cancer
Completed·—·Phase 2·NCT03051659·90 enrolled
Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer
Suspended·—·Phase 3·NCT02037529·201 enrolled
Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer
Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 3·NCT06255392·200 enrolled
Maintenance Treatment With Eribulin Mesylate Versus Observation in Triple Negative Breast Cancer Patients
Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT04502680·100 enrolled
Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer
Completed·—·Phase 1·NCT02120469·27 enrolled
Treatment of Brain Metastases From Breast Cancer With Eribulin Mesylate
Completed·—·Phase 2·NCT02581839·9 enrolled
Halaven Patient Registry (Metastatic Breast Cancer, MBC)
Unknown status·—··NCT03245112·500 enrolled
Eribulin Combined With Anlotinib in Metastatic HER2 Negative Breast Cancer
Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT04624711·40 enrolled
Patients With Advanced Solid Tumors3 trials
Triple-Negative Breast Cancer3 trials
22 more indications
Cervical Cancer1 trial
Lymphoma1 trial
Brain Tumors1 trial
Neuropharmacokinetics of Eribulin Mesylate in Treating Patients With Primary or Metastatic Brain Tumors
Completed·—·Phase 1·NCT02338037·8 enrolled
Bladder Cancer1 trial
Recurrent Head and Neck Cancer1 trial
Liposarcoma1 trial
Small Cell Lung Cancer1 trial
Advanced Solid Tumors1 trial
Salivary Gland Cancer1 trial
Metastatic Cancer1 trial
Metastatic1 trial
A Study Combining Eribulin Mesylate With Avelumab in Cisplatin Ineligible Metastatic Urothelial Cell Cancer Patients
Terminated·—·Phase 1·NCT03502681·6 enrolled
Metastatic Prostate Cancer1 trial
Metastatic Urothelial Cancer1 trial
Metastatic Solid Tumors1 trial
Pancreatic Cancer1 trial
Non-Small Cell Lung Cancer1 trial
Fallopian Tube Cancer1 trial
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Halaven drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Eribulin Mesylate. EMBL-EBI & Wellcome Sanger Institute.
- [5]